- Home
- MIRM vs BSTZ Comparison
MIRM vs BSTZ Comparison
Compare MIRM & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- BSTZ
- Stock Information
- Founded
- MIRM 2018
- BSTZ 2019
- Country
- MIRM United States
- BSTZ United States
- Employees
- MIRM N/A
- BSTZ N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- BSTZ Trusts Except Educational Religious and Charitable
- Sector
- MIRM Health Care
- BSTZ Finance
- Exchange
- MIRM Nasdaq
- BSTZ Nasdaq
- Market Cap
- MIRM 1.9B
- BSTZ 1.6B
- IPO Year
- MIRM 2019
- BSTZ N/A
- Fundamental
- Price
- MIRM $44.50
- BSTZ $20.65
- Analyst Decision
- MIRM Strong Buy
- BSTZ
- Analyst Count
- MIRM 13
- BSTZ 0
- Target Price
- MIRM $57.00
- BSTZ N/A
- AVG Volume (30 Days)
- MIRM 340.6K
- BSTZ 303.2K
- Earning Date
- MIRM 11-12-2024
- BSTZ 01-01-0001
- Dividend Yield
- MIRM N/A
- BSTZ 8.31%
- EPS Growth
- MIRM N/A
- BSTZ N/A
- EPS
- MIRM N/A
- BSTZ 0.71
- Revenue
- MIRM $307,028,000.00
- BSTZ N/A
- Revenue This Year
- MIRM $73.07
- BSTZ N/A
- Revenue Next Year
- MIRM $27.98
- BSTZ N/A
- P/E Ratio
- MIRM N/A
- BSTZ $26.69
- Revenue Growth
- MIRM 112.14
- BSTZ N/A
- 52 Week Low
- MIRM $23.14
- BSTZ $14.11
- 52 Week High
- MIRM $48.89
- BSTZ $19.43
- Technical
- Relative Strength Index (RSI)
- MIRM 65.32
- BSTZ 56.53
- Support Level
- MIRM $41.09
- BSTZ $20.95
- Resistance Level
- MIRM $48.89
- BSTZ $21.40
- Average True Range (ATR)
- MIRM 2.16
- BSTZ 0.29
- MACD
- MIRM 0.57
- BSTZ 0.02
- Stochastic Oscillator
- MIRM 59.09
- BSTZ 48.68
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.